FEMY News & Events

Femasys announced a partnership with Refuah Health Center to offer FemaSeed as a first step in the infertility treatment process. "This partnership is an important step forward in expanding the commercial availability of FemaSeed within community-based fertility care," said Kathy Lee-Sepsick, Chief Executive Officer of Femasys. "With Refuah's trusted care model and strong patient engagement, we expect to accelerate adoption of FemaSeed by providing a more accessible, cost-effective, and patient-centered starting point for fertility treatment."

Femasys files to sell 68.42M shares of common stock for holders

Femasys announced it has received 510(k) clearance from the United States Food and Drug Administration, FDA, for its FemVue Controlled device, an innovative diagnostic solution designed for controlled contrast delivery to evaluate fallopian tube status. "This FDA clearance represents an important milestone for Femasys as we continue to advance practical, clinician-focused innovations," said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys. "FemVue Controlled reflects our commitment to simplifying care delivery while strengthening the scalability and efficiency of our product portfolio."